Equities
  • Price (EUR)9.50
  • Today's Change0.35 / 3.83%
  • Shares traded400.00
  • 1 Year change-29.63%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year AVITA Medical Inc had net income fall 32.69% from a loss of 26.67m to a larger loss of 35.38m despite revenues that grew 45.68% from 34.42m to 50.14m over the same period.
Gross margin86.80%
Net profit margin-92.04%
Operating margin-100.50%
Return on assets-57.22%
Return on equity-107.66%
Return on investment-68.00%
More ▼

Cash flow in USDView more

In 2023, AVITA Medical Inc increased its cash reserves by 21.77%, or 3.95m. Cash Flow from Financing totalled 40.37m or 80.52% of revenues. In addition the company used 38.01m for operations while cash from investing totalled 1.61m.
Cash flow per share-1.92
Price/Cash flow per share--
Book value per share0.9216
Tangible book value per share0.9006
More ▼

Balance sheet in USDView more

AVITA Medical Inc has a Debt to Total Capital ratio of 63.15%.
Current ratio5.29
Quick ratio4.81
Total debt/total equity1.71
Total debt/total capital0.6315
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.